MDMA, psychedelic mushroom studies to move to recruitment phase

Image: Shutterstock

Dr Bright said Australia had the opportunity to “scale up”, with bigger trials ensuring more therapists were trained so when MDMA was given the green light in the US, the safety data was available to show it was possible here too.

He said currently none of the Australian studies had been given government funding and there was little incentive for pharmaceutical companies to back this research either.

Dr Bright said he was concerned that if the infrastructure for administering these drugs wasn’t worked into Australia’s health care system, the treatments would be limited to those who could afford them.

Click here to read the full article by Alex Crowe

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search